The Challenge of microRNA as a Biomarker of Epilepsy.
The Challenge of microRNA as a Biomarker of Epilepsy.
复制标题
microRNA 作为癫痫生物标志物的挑战。
DOI：
10.2174/1570159x15666170703102410
复制
发表时间：
2018
影响因子：
5.3
通讯作者：
Ma Y
中科院分区：
文献类型：
--
作者：
Ma Y
癫痫是一种反复发作的慢性严重神经系统疾病。而目前抗癫痫药物的有效性仅为1/3以下，且特异性抗癫痫药物治疗时无生物标志物预测。最新的研究表明，miRNA可能是2000年初开始的癫痫发病机制的关键。与癫痫治疗方法相关的几个miRNA靶基因及作用途径。 我们使用术语“epilepsy AND microRNA AND biomarkers”和“seizure AND microRNA AND biomarkers”检索PubMed，检索时间为2000年1月1日至2017年1月1日。我们选择的文章，在体内癫痫模型和患者的特点新的miRNAs。然后，我们根据对可能与癫痫相关的质量和机制见解的主观评价，选择最相关的文章。 hsa-miR-134的表达降低可能是一种潜在的非侵入性生物标志物，用于癫痫患者的诊断，并可用于区分癫痫患者和非癫痫患者。miR-181 a在急性期表达明显下调，而在慢性期和潜伏期表达上调，但变化不大，这种现象在不同阶段的出现情况如何仍有待进一步探讨。此外，miR-146 a在患者血清中的表达也呈下调趋势，miR-124、miR-199 a、miR-128等可能成为未来的候选生物标志物。miR-15 a-5 p和miR-194 - 5 p在癫痫患者中表达下调，有可能作为一种新的生物标志物用于癫痫的诊断。 这些观察结果为癫痫患者的诊断和治疗提供了新的发展机会。先进的技术和miRNA的结合可能在癫痫等疾病中发挥更有效的作用。这些报道将有助于解决miRNAs作为癫痫生物标志物的应用和新的治疗方法。总之，研究人员应该关注miRNAs，了解癫痫的病因，治疗和诊断。对这些药物功效的任何这些影响的探索是值得的。
Epilepsy is one of chronic severe neurological disorders possess to recurring seizures. And now anti-epileptic drugs are only effective in less than one third of epilepsy patients, and biomarkers predicting are not available when the specific antiepileptic drugs treated. Advanced studies have showed that miRNA may be a key in the pathogenesis of epilepsy beginning in the early 2000 years. Several target genes and pathways of miRNA which related to the therapeutic methods to epilepsy. We searched PubMed from Jan 1,2000 to Jan 1,2017, using the terms “epilepsy AND microRNA AND biomarker” and “seizure AND microRNA AND biomarker”. We selected articles that featured novel miRNAs in vivo epilepsy models and patients. We then selected the most relevant articles based on a subjective appraisal of their quality and mechanistic insight that could be relevant to epilepsy. Decrease the expression of has-miR134 could be a potential non-invasive biomarker to use in diagnosis for the epilepsy patients for using hsa-miR-134 also be identified to distinguish patients with and without epilepsy. miR-181a show significant downregulation in the acute stage, but up regulation in the chronic stage and in the latent stage there is no changing and how about this phenomenon appearance in different stage still should be discussed in the future. Besides that, miR-146a can down-regulated in the patients using genome-wide for serum in circulating miRNAs.miR-124, miR-199a, and miR-128 etc. could be a candidate for the biomarker in future. miR-15a-5p and -194-5p down-regulated in epilepsy patients, in the future, it may be used as a novel biomarker for improve diagnosis. These observations give a chance that new development for diagnosis and treatment of epilepsy patients. Advanced technique and miRNA combination may product more effective roles in epilepsy and other disease. These reports will be available to solve the application of miRNAs as biomarkers and novel therapy approaches for epilepsy. In summary, researcher who focus on miRNAs should be understanding of the causes, treatment, and diagnosis of epilepsy. exploration of any of these effects on the efficacy of these drugs is worthwhile.